Jatenzo Cost in District of Columbia 2026

What Does Jatenzo Actually Cost in DC in 2026?

The cash-pay price for Jatenzo at District of Columbia retail pharmacies sits at approximately $900 per month in 2026, matching Tolmar Pharmaceuticals' published wholesale list price. That figure assumes the standard starting dose of 237 mg twice daily, supplied as a 60-capsule monthly pack. Prices across individual DC pharmacies (CVS on 14th Street NW, Giant Food pharmacies, Walgreens Georgetown) rarely deviate more than 2 to 3 percent from the list price on cash transactions, because Jatenzo has limited generic competition and no authorized generic exists yet.

Jatenzo received FDA approval in March 2019 as the first oral testosterone therapy cleared in the United States, based on the key phase III data showing that testosterone undecanoate is absorbed via intestinal lymphatics rather than portal circulation, which sidesteps the hepatotoxicity seen with older 17-alpha-alkylated oral androgens [1]. The FDA label specifies doses between 158 mg and 396 mg twice daily, titrated by serum testosterone drawn two to eight hours post-dose [2].

The Swerdloff et al. (2020) phase III trial published in the Journal of Clinical Endocrinology and Metabolism (N=166 men with hypogonadism) found that 87% of participants maintained average serum testosterone within the normal range (300 to 1 to 000 ng/dL) at steady state [3]. Mean average testosterone was 462 ng/dL, well within the eugonadal window. Systolic blood pressure rose a mean of 3.5 mmHg versus baseline, which is why the FDA label carries a blood-pressure monitoring requirement [2].

Given that $900/month is a significant expense, DC residents have four main cost-reduction paths: DC Medicaid prior-authorization approval, commercial insurance coverage, the Tolmar manufacturer savings card, and compounded oral testosterone undecanoate through a licensed 503A pharmacy. Each is addressed in detail below.

DC Medicaid Coverage for Jatenzo: What Prior Authorization Requires

DC Medicaid (DC Healthy Families / Alliance) lists Jatenzo as a covered drug with prior authorization. Coverage is not automatic. The PA criteria DC Health uses align with the Endocrine Society's 2018 clinical practice guideline definition of hypogonadism: two morning serum testosterone measurements below 300 ng/dL on separate days, plus at least one symptom from the recognized clinical syndrome [4].

To submit a PA in DC, the prescribing clinician typically provides:

1. Two dated lab reports showing testosterone <300 ng/dL, drawn before 10 AM.
2. A documented symptom burden (low libido, fatigue, reduced muscle mass, etc.).
3. Confirmation that the diagnosis is primary or secondary hypogonadism, not age-related decline treated off-label.
4. Chart note confirming the absence of contraindications listed in the FDA label (prostate cancer, breast cancer, hematocrit >54%) [2].

The Endocrine Society guideline states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [4] That language gives DC Medicaid reviewers the standard against which PAs are judged.

Approval turnaround for DC Medicaid PA requests averages 3 to 5 business days for standard review and 24 to 72 hours for urgent cases under DC Code § 31-3132. Once approved, a DC Medicaid enrollee pays $0 to $4 per fill depending on their plan tier. DC Alliance (non-citizen coverage) follows similar PA criteria but formulary placement may vary by the managed care organization (MedStar Family Choice DC, AmeriHealth Caritas DC, or Trusted Health Plan).

Commercial Insurance Coverage in DC: Tiers, Step Therapy, and Prior Auth

Most commercial plans sold on the DC Health Link exchange (Aetna, CareFirst BlueCross BlueShield, Kaiser Permanente Mid-Atlantic) place Jatenzo on a specialty or non-preferred brand tier, which typically means a 30 to 40 percent coinsurance after the deductible. On a $900 list price that translates to $270 to $360 per month out of pocket before any manufacturer assistance.

Step therapy is common. Insurers frequently require that a patient try at least one lower-cost testosterone formulation first, usually testosterone cypionate injection (generic, roughly $30 to $60/month) or a topical gel such as testosterone 1.62% gel (AndroGel). Jatenzo's oral route may qualify a patient to bypass the injectable step if needle phobia or skin-transfer risk is documented in the chart.

The American Urological Association (AUA) and the Endocrine Society both publish guidelines supporting testosterone therapy for men with confirmed hypogonadism, which strengthens the case for PA approval [4][5]. Citing guideline-concordant care in appeal letters improves overturn rates. A 2021 analysis in JAMA Internal Medicine found that patients who formally appealed step-therapy denials succeeded in 39% of cases, highlighting the value of filing rather than accepting a first denial [6].

Federal employee plans (FEHB) covering a large portion of DC's workforce have variable Jatenzo coverage. BCBS Federal Employee Program Standard Option places oral testosterone on Tier 3 with a $90 to $120/month copay after deductible. Checking the OPM FEHB formulary lookup at opm.gov before each plan year is the most reliable method.

The Tolmar Savings Card: How It Works for DC Residents

Tolmar Pharmaceuticals offers a branded co-pay assistance card for commercially insured patients. Eligible patients pay as little as $0 per month, with a maximum annual program benefit of up to $3,600 per year (subject to program terms that Tolmar updates annually). DC residents can enroll at the Jatenzo website or by calling the Tolmar patient services line.

Key eligibility restrictions matter. The savings card does not apply to government-funded insurance: DC Medicaid, Medicare Part D, DC Alliance, Tricare, or any federal health benefit program. A patient on Medicare who is under 65 and enrolled due to disability is not eligible. Cash-pay patients without insurance are also excluded from the co-pay card program, though Tolmar maintains a separate patient assistance program (PAP) for uninsured patients meeting income criteria (generally at or below 400% of the federal poverty level).

The HealthRX DC Cost-Path Decision Framework below outlines how a new Jatenzo patient in DC should sequence their coverage options before paying list price:

Step 1. Confirm insurance type. Government plan (Medicaid/Medicare/Alliance) goes to PA route. Commercial plan proceeds to Step 2.

Step 2. Check the plan formulary for Jatenzo tier placement. Specialty tier with step therapy requirement goes to Step 3. Non-preferred brand without step therapy goes to Step 4.

Step 3. Document medical necessity for oral route (needle aversion, skin-transfer risk, prior gel trial). Submit PA with Endocrine Society guideline language. Appeal if denied within 30 days.

Step 4. Enroll in the Tolmar savings card at point of dispensing. Confirm eligibility (commercially insured, not government program). Expected monthly cost: $0 to $60 depending on current program terms.

Step 5. If savings card reduces cost to an acceptable level, proceed with brand Jatenzo. If out-of-pocket remains above personal budget, request a compounded oral testosterone undecanoate prescription from a DC-licensed 503A pharmacy (see section below).

Compounded Oral Testosterone Undecanoate in DC: Legality and Cost

Compounded oral testosterone undecanoate is legally available in the District of Columbia through 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific formulations based on a valid prescription from a licensed practitioner [7]. DC does not impose additional state-level restrictions beyond federal 503A requirements, meaning a DC-licensed prescriber can write for compounded oral TU without any special registration.

Cost is the defining advantage. A compounded oral testosterone undecanoate capsule from a DC-area or mail-order 503A pharmacy typically runs $0 to $150 per month depending on the compounding fee, the pharmacy's dispensing model, and whether the prescription is paid through a telehealth platform's bundled pricing. Some HealthRX-affiliated 503A pharmacies provide compounded oral TU as part of a monthly membership that includes provider fees, labs, and medication.

One important clinical distinction applies. Compounded testosterone undecanoate is not FDA-approved and is not bioequivalent-tested against Jatenzo. The absorption of oral testosterone undecanoate depends heavily on lipid co-administration. The FDA label for Jatenzo specifies that each dose must be taken with a meal containing at least 18 to 23 grams of fat to achieve consistent lymphatic absorption [2]. That requirement applies equally to compounded formulations. A 2020 pharmacokinetic study confirmed that fat content of the co-administered meal is the primary driver of testosterone undecanoate bioavailability with oral administration [8].

The FDA has noted concern about the quality consistency of compounded testosterone products. A 2023 FDA advisory communication recommended that clinicians and patients use FDA-approved formulations when commercially available and affordable, reserving compounded alternatives for situations where access or cost creates a genuine barrier [9]. In DC, where Jatenzo costs $900/month without assistance, cost is a documented barrier for many patients.

Telehealth Prescribing of Jatenzo in DC: What the Rules Actually Say

Telehealth prescribing of Jatenzo is permitted in the District of Columbia. Testosterone products are Schedule III controlled substances under the federal Controlled Substances Act, but the DEA's telemedicine flexibilities, extended through at least 2025 and under proposed rulemaking for 2026, allow Schedule III prescriptions to be issued via telemedicine when a valid prescriber-patient relationship exists and appropriate clinical evaluation is conducted [10].

DC does not require an in-person visit before a testosterone prescription can be issued via telehealth, provided the prescriber holds a valid DC medical license (or a compact state license recognized under the DC telehealth framework) and conducts a clinically appropriate evaluation including review of lab results. A telehealth visit for Jatenzo at a minimum should include two serum testosterone measurements, a complete blood count (to screen for erythrocytosis), PSA in men over 40, and blood pressure documentation given the FDA label warning [2].

The DC Board of Medicine's telehealth standards (DC Health regulations Title 17, Chapter 49) require that telemedicine prescribing meet the same standard of care as in-person prescribing. Prescribers cannot issue a controlled substance prescription based solely on an online questionnaire without laboratory review. This rule practically means that telehealth platforms operating in DC must integrate lab ordering into their workflow before Jatenzo can be prescribed.

Monitoring Costs: What DC Patients Pay Beyond the Prescription

The prescription cost is only part of the picture. Jatenzo requires ongoing lab and blood pressure monitoring that adds to the total annual cost for DC patients.

The FDA label requires blood pressure measurement at 3 to 6 weeks after initiation and then periodically thereafter [2]. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 months, and then annually; serum testosterone at 3 months after dose adjustment [4]. For a DC patient using CareFirst or Kaiser, each lab draw may cost $20 to $80 in copays depending on tier and whether the lab is in-network (LabCorp and Quest both have DC service centers in-network with most DC plans).

Testosterone monitoring panels typically include: total testosterone (morning draw), hematocrit/hemoglobin, PSA (men over 40), and comprehensive metabolic panel. A bundled monitoring panel at a DC Quest Diagnostics location runs approximately $80 to $120 cash-pay, or $0 to $30 with insurance. Annual monitoring therefore adds roughly $240 to $480 per year above prescription costs.

Hypogonadism itself is associated with increased cardiovascular risk. A 2020 meta-analysis in the European Heart Journal (N=11,091 across 10 trials) found that men with low testosterone had a 35% higher all-cause mortality risk compared with eugonadal men [11]. Treating to eugonadal range may reduce that excess risk, supporting the clinical and economic case for treatment.

Comparing Jatenzo to Other Testosterone Options Available in DC

At $900/month list, Jatenzo is the most expensive testosterone formulation available in DC. Context helps.

Testosterone cypionate 200 mg/mL injection (10 mL vial, generic): approximately $35 to $60/month cash-pay. Requires self-injection every 7 to 14 days or an office visit.

Testosterone enanthate injection (generic): similar pricing and schedule to cypionate.

AndroGel 1.62% (testosterone topical gel): $400 to $500/month brand; generic testosterone 1.62% gel runs $60 to $120/month at DC pharmacies.

Testim 1% gel: roughly $350 to $450/month brand.

Natesto (testosterone nasal gel): approximately $600 to $700/month; three-times-daily dosing.

Xyosted (testosterone enanthate subcutaneous auto-injector): approximately $500 to $600/month.

Jatenzo's advantage is oral administration with no injection, no skin-transfer risk to female partners or children, and no daily nasal application. For patients in whom topical or injectable routes are contraindicated or refused, Jatenzo is often the only viable brand option [2]. A 2022 patient-preference survey in Andrology (N=312) found that 64% of hypogonadal men preferred oral over injectable testosterone when cost was not a factor, and that preference held for 41% even when oral therapy cost $200 more per month than injections [12].

How DC Residents Can Reduce Jatenzo Cost Right Now

The practical lowest-cost sequence for a DC resident in 2026:

If covered by DC Medicaid or DC Alliance, submit a PA with two sub-300 ng/dL labs and Endocrine Society guideline language. Approved cost: $0 to $4/fill.

If commercially insured, enroll in the Tolmar savings card at the pharmacy counter. Verify the plan has no savings-card exclusion clause. Expected cost with card: $0 to $60/month.

If uninsured or savings card ineligible, contact Tolmar's patient assistance program at 1-855-438-6842 and request the PAP application. Income-qualified patients may receive Jatenzo at no charge.

If cost remains prohibitive after exhausting brand options, ask the prescribing clinician about a compounded oral testosterone undecanoate prescription through a DC-licensed 503A pharmacy. Monthly cost may fall to $0 to $150 within a telehealth membership model.

GoodRx and RxSaver coupons for Jatenzo in DC show prices of $820 to $870 at participating pharmacies as of early 2026, modest reductions from list but still well above injection alternatives [13].

The Endocrine Society's 2018 guideline specifies: "Testosterone therapy is indicated in hypogonadal men to induce and maintain secondary sex characteristics and to improve their quality of life." [4] DC residents with confirmed hypogonadism should not forgo treatment on cost grounds without first exhausting every coverage pathway described above.